Welcome to the e-CCO Library!

DOP75: Effectiveness and Safety of tofacitinib versus vedolizumab in Patients with Ulcerative Colitis; A Nationwide, ICC Registry study
Year: 2022
Source: ECCO'22
Authors: Straatmijer , T.(1);Visschedijk , M.(2);de Vries , A.(3);Hoentjen , F.(21);van Bodegraven , A.A.(5);Bodelier , A.G.L.(6);de Boer , N.K.H.(7);Dijkstra , G.(2);Festen , E.A.M.(2);Horjus , C.(8);Jansen , J.M.(9);Jharap , B.(10);Mares , W.(11);Oldenburg , B.(12);Ponsioen , C.Y.(13);Romkens , T.E.H.(14);Srivastava , N.(15);van der Voorn , M.M.(16);West , R.L.(17);van der Woude , J.C.(3);Wolvers , M.D.J.(18);Pierik , M.(19);van der Meulen , A.E.(20);Duijvestein , M.(4);
Created: Friday, 11 February 2022, 3:52 PM
DOP75: Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA
Year: 2024
Source: ECCO'24 Stockholm
Authors: Rubín De Célix, Cristina
Created: Tuesday, 30 April 2024, 5:03 PM
DOP75: Loss-of-response and immunogenicity following immunomodulator withdrawal from anti-tumour necrosis factor alpha combination therapy: Results from a large retrospective cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Mahmoud, R.(1);Schultheiss, J.(1);Louwers, J.(1);van der Kaaij, M.(1);van Hellemondt, B.(1);Mahmmod, N.(2);van Boeckel, P.(2);Jharap, B.(3);Fidder, H.(1);Oldenburg, B.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP75: Surgery and hospitalisations rates in inflammatory bowel disease patients in the Québec provincial database from 199–6 to 2015
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Verdon*1, J. Reinglas1, J. Coulombe2, L. Gonczi3, T. Bessissow1, W. Afif1, M. Vutcovici4, G. Wild1, E. Seidman1, A. Bitton1, P. Brassard5,6, P. Lakatos1

Created: Friday, 22 February 2019, 9:41 AM
DOP75: Video capsule endoscopy may detect active small bowel Crohn's disease requiring change of treatment despite unremarkable ileo-colonic anastomosis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Thurm, T.(1,2)*;Zmora, N.(1,2,3);Hirsh, A.(1,2);Deutsch, L.(1,2);Maharshak, N.(1,2);
Created: Friday, 14 July 2023, 10:43 AM
DOP76 Corticosteroid sparing effects of ustekinumab therapy for ulcerative colitis through 2 years: UNIFI long-term extension
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Peyrin-Biroulet1, W. Sandborn2, B. Sands3, E. Scherl4, C. Marano5, C. O’Brien5, H. Zhang6, J. Johanns6, Y. Zhou6, M. Abreu7, R.P. Arasaradnam8, D.S. Rowbotham9, R.W.L. Leong10, S. Danese11, UNIFI Investigators

Created: Thursday, 30 January 2020, 10:12 AM
DOP76: Comparison of healing of complex perianal Crohn´s disease fistulas by advancement flap and mesenchymal stem cell therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Zuzana Serclova
Created: Friday, 14 July 2023, 2:22 PM
DOP76: Comparison of healing of complex perianal Crohn´s disease fistulas by advancement flap and mesenchymal stem cell therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Serclova, Z.(1)*;Tremerova, A.(2);Lengalova, M.(2);Petra, Z.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP76: Corticosteroid sparing effects of ustekinumab therapy for Ulcerative Colitis through 2 years: UNIFI long-term extension
Year: 2020
Source: ECCO'20 Vienna
Authors: Laurent Peyrin-Biroulet
Created: Tuesday, 23 June 2020, 5:40 PM
Last Modified: Wednesday, 24 June 2020, 12:03 PM by Eloise Lanaud
DOP76: Corticosteroid sparing effects of ustekinumab therapy for Ulcerative Colitis through 2 years: UNIFI long-term extension
Year: 2020
Source: ECCO'20 Vienna
Authors: Laurent Peyrin-Biroulet
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP76: No durable impact of COVID-19 on disease activity and microbiome composition in patients with IBD
Year: 2021
Source: ECCO'21 Virtual
Authors: Funez-dePagnier, G.(1);Lima, S.(1);Duenas-Bianchi, L.(1);Lai, D.(1);Ahmed, W.(1);Battat, R.(1);Scherl, E.(1);Lukin, D.(1);Longman, R.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP76: Prevalence and health-care costs of perianal fistulas in Crohn’s disease in a nationwide cohort
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Niels Qvist
Created: Tuesday, 28 May 2019, 3:32 PM
Epidemiology, Crohn’s disease, Health economic analysis, Perianal disease
Files: 1
DOP76: Prevalence and healthcare costs of perianal fistulas in Crohn’s disease in a nationwide cohort
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Nordholm-Carstensen*1, N. Qvist2, B. Højgaard3, C. Halling3, M. Carstensen4, N-P. Ipland4, J. Burisch5

Created: Friday, 22 February 2019, 9:41 AM
DOP76: Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent
Year: 2022
Source: ECCO'22
Authors: Buisson, A.(1);Nachury, M.(2);Fumery, M.(3);Guilmoteau, T.(1);Leclerc, E.(1);Altwegg, R.(4);Serrero, M.(5);Mathieu, N.(6);Treton, X.(7);Vuitton, L.(8);Pereira, B.(9);Amiot, A.(10);Bouguen, G.(11);
Created: Friday, 11 February 2022, 3:52 PM
DOP77 Ustekinumab is associated with better effectiveness outcomes when compared with vedolizumab in Crohn’s disease patients with prior anti-TNF failure: comparative effectiveness study from the ICC Registry
Year: 2020
Source:

ECCO'20 Vienna

Authors:

V. Biemans drs1, J. van der Woude2, G. Dijkstra3, A. van der Meulen- de Jong4, M. Löwenberg5, N. de Boer6, B. Oldenburg7, N. Srivastava8, J. Jansen9, A. Bodelier10, R. West11, A. de Vries2, J. Haans12, D. de Jong13, F. Hoentjen13, M. Pierik12, on behalf of the Dutch Initiative on Crohn and Colitis (ICC)

Created: Thursday, 30 January 2020, 10:12 AM
DOP77: Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn´s Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD study
Year: 2022
Source: ECCO'22
Authors: Di Giuseppe, R.(1);Plachta-Danielzik, S.(2);Bokemeyer, B.(3);Efken, P.(4);Mohl, W.(5);Hoffstadt, M.(6);Krause, T.(7);Schweitzer, A.(8);Schnoy, E.(9);Atreya, R.(10);Teich, N.(11);Trentmann, L.(12);Ehehalt, R.(13);Franzenburg, S.(2);Hartmann, P.(4);Schreiber, S.(14);
Created: Friday, 11 February 2022, 3:52 PM
DOP77: Effect of Inflammatory Bowel Disease and Related Medications on COVID-19 Incidence, Disease Severity, and Outcome -The Israeli Experience
Year: 2021
Source: ECCO'21 Virtual
Authors: Richter, V.(1);Bermont, A.(1);Cohen, D.L.(1);Broide, E.(1);Shirin, H.(1)
Created: Wednesday, 2 June 2021, 4:12 PM